Dabigatran Preparation via Crystallization Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing method for producing dabigatran, an anticoagulant, faces challenges with low purity and yield due to complex and inefficient chromatographic purification of intermediate products, making it difficult to achieve high-quality pharmaceutical-grade dabigatran on an industrial scale.
Innovation Solution
The method involves preparing dabigatran using new intermediates in the form of solvates and dihydrochlorides, which allows for crystallization-based purification instead of chromatographic methods, significantly improving the purity and yield of dabigatran by transforming intermediates VII-HCl and VII-2HCl into high-purity forms through acidic hydrolysis and reactions with hexyl chloroformate in inert solvents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromatographic purification is used to purify intermediate compounds VI and VII, then purity can be improved, but the process complexity and cost increase significantly, and yield decreases
Solution Approach 1:
The patent changes the physical-chemical parameters of the intermediate compounds by converting them into specific salt forms (hydrochloride, oxalate, sulfate) that have improved crystallization properties. This allows purification by crystallization instead of chromatography, resolving the contradiction between purity and process complexity
Solution Approach 2:
The patent replaces expensive and complex chromatographic purification systems with simple, inexpensive crystallization processes using common solvents. This disposable-like approach uses readily available materials to achieve high purity without requiring sophisticated equipment
2Manufacturing precision
If chromatographic purification is used for intermediate compounds, then purity can be improved, but production time and cost increase
Solution Approach 1:
By changing the chemical form of intermediates to salt forms with better solubility characteristics, the patent enables rapid crystallization-based purification that is much faster than chromatography, thereby improving productivity while maintaining high purity
Solution Approach 2:
The patent performs preliminary formation of salt forms with controlled solubility properties before the final purification step. This preliminary action prepares the compounds for efficient crystallization, reducing the time required for purification and increasing overall production efficiency
3Manufacturing precision
If conventional purification methods are used, then some purity can be achieved, but yield and economic viability decrease
Solution Approach 1:
The patent changes the solubility parameters of intermediates by forming salts with specific solvents, enabling crystallization that achieves high purity with minimal material loss. This resolves the contradiction between purity and yield by finding optimal solvent systems where the desired product crystallizes cleanly
Solution Approach 2:
The patent utilizes phase transitions (crystallization from solution) as the primary purification mechanism. By controlling the phase transition conditions through salt formation and solvent selection, high purity products are obtained with excellent yield, avoiding the material losses associated with chromatographic methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the purity of dabigatran to 96-98% and increases yield, simplifying the production process by replacing chromatographic purification with crystallization, thereby improving the economic viability and efficiency of dabigatran production.
Implementation Method 1
acidic hydrolysis of the nitrile function of compound VI
Implementation Method 2
the monohydrochloride of compound VII in the form of a solvate with ethanol
Data Source
AI summary
Intermediates for the preparation of dabigatran of formulae (VII-2HCl) and (VII-HCl), methods for their preparation and a method for preparation of dabigatran of formula (VIII) using these intermediates.